Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Sionna Therapeutics, Inc. (NASDAQ: SION) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Sionna Therapeutics, Inc. (NASDAQ: SION) is now covered by analysts at Guggenheim. They set a "buy" rating and a $45.00 price target on the stock.
Sionna Therapeutics, Inc. (NASDAQ: SION) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $32.00 price target on the stock.
Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference